Skip to search formSkip to main contentSkip to account menu

Neihulizumab

A humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1; SELPLG; CD162), with potential immunosuppressive… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mo1856 A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE, ANTI-TNF ALPHA AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)